| (D) |   1. |  ¤@¦ì17·³¤k©Ê±wªÌ¡A¦]¦³©ü¯t¡A¦hµo©ÊÃö¸`¯kµh¤Î¤UªÏ¯B¸~¦Ó¦í°|¡CANA 1:320 speckled¡A¦å²G±`³W¡GRBC 2.87M/£gL¡AWBC
2.84K/£gL¡A platelet 124K¡C§¿²G±`³WÀˬdµo²{¡Gproteinuria ¡Ù300 mg/dL¡A§¿¨H´íRBC 40-50/HPF¡AWBC 20-30/HPF¡Ahyaline cast
3-5/HPF¡CµÇŦ¬¡ÅéÀˬdªºµ²ªG(¨£
·Ó¤ùA©M
·Ó¤ùB)¬°¡G(A)¿Ã¥ú§ÜÅé¬V¦â (B)H&E¬V¦â¡C½Ð°Ý³o¦ì±wªÌªº³Ì¥i¯à¶EÂ_¬°¡G | 
| A. | Acute pyelonephritis | 
| B. | Amyloidosis | 
| C. | Multiple myeloma | 
| D. | Lupus nephritis | 
| E. | Post-streptococcal glomerulonephritis | 
|   | 
| (E) |   2. | ¡]©Ó«eÃD¡^½Ð°Ý¤U¦Cªº¦óºØªvÀø¹ï¯f¤H³Ì¬°¾A·í¡H | 
| A. | Pencillin G IV injection | 
| B. | Oral melphalan | 
| C. | High dose oral glucocorticoids | 
| D. | Oral cyclosporine | 
| E. | Cyclophosphamide pulse therapy | 
|   | 
| (A) |   3. | ¦³¤@¦ì33·³ªº¤k©Ê±wªÌ¡A¦b¤G¦~«e¶}©lµoı¥V¤Ñ¨â¤â«üºÝ·|¦³µo¥Õ¡Bµoµµ²{¶H¡C³Ìªñ¤@¦~¨Ó®É±`¦³¦hµo©ÊÃö¸`»Äµh¡AÅé«´î»´¤Î¸zG¤£¾A¡C³Ìªñ¥b¦~¨Ó¦³§]Ã`§xÃø¤ÎÁy³¡©M¤â«üªº¥Ö½§Á^ºò¤Î½§¦âÅܶ¡C¦b¨D¶E«e¤@Ӥ릳°®«y¤Î¹B°Ê©Ê©I§l§xÃø¡C½Ð°Ý³Ì¥i¯àªº¶EÂ_¬°¡G | 
| A. | Progressive systemic sclerosis | 
| B. | Systemic lupus erythematosus | 
| C. | Dermatomyositis | 
| D. | Rheumatoid arthritis | 
| E. | Idiopathic pulmonary fibrosis | 
|   | 
| (B) |   4. | ¡]Äò«eÃD¡^¤Wz±wªÌ¦í°|¤§«áªºÀˬdµ²ªG¦p¤U¡GANA 1:1280 nucleolar pattern¡AIgG 2042 mg/dL¡AIgA 365 mg/dL¡AIgM 156 mg/dL¡FPFT¡Gmoderate restrictive ventilatory defect with 56% of predicted DLCO¡Fesophageal motility test Åã¥Ü¹¹D¤U³¡ 2/3 ¦³¤£¥¿±`į°Ê¡C¸Õ°Ý¤U¦C¦óºØÃĪ«¹ï¦¹±wªÌ³Ì¦³À°§U¡H | 
| A. | Salazopyrine | 
| B. | D-penicillamine | 
| C. | Methotrexate | 
| D. | IVIG | 
| E. | Calcium channel blocker | 
|   | 
| (C) |   5. | ¤@¦ì46·³ªºRA±wªÌ¡A¨â°¼¤â«ü¦³ulnar deviation¤Î¤âµÃ³¡©Tª½¡]ankylosis¡^¡A¨¬³k¥ç¦³ÅܧΤΨ¬½ï³¡¸~µÈ¡C¦³¤@¤Ñ¦¤W¿ô¨Óµoı¥ª¤â²Ä¢¼¤Î¢½«ü¤U««µLªk¤WÁ|¡C¦Ó¥k¸}¤]µL¤O¤Î·Pı²§±`¡C©â¦åÀˬdµo²{RF 1810 IU/mL¡AC3 54.7 mg/dL¡AC4 8.4 mg/dL¡ACRP 11.7 mg/dL¡C½Ð°Ý³o¦ì±wªÌªº¥i¯à¶EÂ_¬°¡G | 
| A. | Entrapment syndrome | 
| B. | ¥ª¤â²Ä¢¼¡B¢½«ü¶¡šj±a¤Î¥k¨¬ Achilles tendon Â_µõ | 
| C. | Mononeuritis multiplex | 
| D. | Atlanto-axial subluxation | 
| E. | Rheumatoid nodules formation in the above sites | 
|   | 
| (D) |   6. | ¡]Äò«eÃD¡^¬°¤F¶i¤@¨B½T©w¶EÂ_¡A½Ð°ÝÀ³¸Ó§@¤U¦Cªº¨º¤@ºØÀˬd³Ì¦³À°§U¡H | 
| A. | ¦å¤¤¦Ù¦×»Ã¯ÀªºÀˬd | 
| B. | ÀV´ÕX-¥ú·Ó¬Û¡]¥]¬Ahyperextension¤Îhyperflexion¡^ | 
| C. | ·Æ²G½¤ªº¥ÍÀˤÁ¤ù | 
| D. | ¦Ù¹q¹Ï¤Î¯«¸g¹ï¾É³t«×´ú©w | 
| E. | ¿©±w³¡¦ìªº¶WµªiÀˬd | 
|   | 
| (C) |   7. | ¤U¦C¦óºØ¦Ù¦×»Ã¯À¹ïµû¦ô¦hµo©Ê¦Ùª¢±wªÌªº¦Ù¦×µoª¢µ{«×³Ì¬°±Ó·P¡H | 
| A. | Aldolase | 
| B. | Lactic dehydrogenase | 
| C. | Creatine kinase | 
| D. | Glutamate pyruvate transaminase | 
| E. | Glutamic-oxaloacetic transaminase | 
|   | 
| (E) |   8. | ¤U¦C¦³Ãö rheumatoid arthritis¡]RA¡^ÃĪ«ªvÀøªº´yz¡A¦óªÌ¥¿½T¡H | 
| A. | NSAIDs ¥i¥H¨¾¤î°©ÀYªº«I»k | 
| B. | TNF-£\ neutralizing agents¥i¥H§@¬°²Ä¤@½uÃĪ«¨Ó¨Ï¥Î | 
| C. | Ãþ©T¾J¹ïRAªº¯gª¬½w¸Ñ¬Û·í¦³®Ä¡A°ß¨Ï¥Î¾¯¶q¥²¶·¤j©ó0.5 mg/kg/day | 
| D. | ·í¨Öµo¦³rheumatoid interstitial lung fibrosis®É¡Amethylprednisolone pulse therapy¦³¬Û·íªºÀø®Ä | 
| E. | DMARDs¤¤¥Hmethotrexateªº¨Ï¥Î§@¬°°ò¥Û | 
|   | 
| (A) |   9. | ¸Õ°Ý¤U¦Cªº¦ÛÅé§ÜÅé»P¦ÛÅé§K¬Ì¯e¯fªº°t¹ï¤¤¡A¦óªÌ¤£¥¿½T¡H | 
| A. | Anti-Jo-1---PSS | 
| B. | Anti-centromere ---CREST syndrome | 
| C. | cANCA---Wegener's garnulomatosis | 
| D. | Anti-ds DNA --- SLE | 
| E. | Anti-U1 RNA --- MCTD | 
|   | 
| (B) |  10. | ¦³¤@¦ì23·³ªº¤k©Ê±wªÌ¿©±wSLE¤w¦³¥|¦~¤§¤[¡C¤T¤Ñ«e®a¤Hµo²{¦oªº¤f¾¦¤£²M¡A¦Ó¥B¥ª¤â¦³©âÝzµo¥Í¡A¦ýµL·NÃѳॢ¡C¦í°|¤§«á©â¦åÀˬdªºµ²ªG¦p¤U¡GANA 1:160 speckled¡Aanti-ds DNA 43.7 IU/mL¡AC3/C4=68.5/7.6 mg/dL¡AWBC 4700/£gL¡C½Ð°Ý¤U¦Cªº¨º¤TºØÀˬd³Ì¦³À°§U¡H(1)CSF (2) EEG (3) brain CT scan (4) MRI with contrast medium (5) anti-ENA (6) anti-cardiolipin antibodies | 
| A. | 1 + 2 + 3 | 
| B. | 1 + 4 + 6 | 
| C. | 2 + 3 + 5 | 
| D. | 3 + 4 + 6 | 
| E. | 4 + 5 + 6 | 
|   |